CoChat

Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone

Weiden, Peter J., Daniel, David G., Simpson, George, Romano, Steven J. · 2003 · Journal of Clinical Psychopharmacology
Cited by 123

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Side effect and health status changes were measured in 3 studies in which outpatients experiencing suboptimal efficacy or tolerability with their current antipsychotic were switched to 6 weeks of open-label ziprasidone. The studies differed only in the patient's prior antipsychotic; 1 study group was on olanzapine (n = 104), a second on risperidone (n = 58), and third on a conventional antipsychotic (n = 108). Baseline and end point health status measures included weight and height, nonfasting cholesterol, and triglyceride levels, prolactin levels, and extrapyramidal side effects. Improvements in health indices and side effects were seen among all 3 groups, but the specific benefits depended on the preswitch antipsychotic. For example, patients switched from olanzapine experienced a mean weight loss of 1.76 kg (P < 0.0001), those switched from risperidone had a lesser reduction in weight (-0.86 kg; P = 0.015), and those switched from conventionals had a nonsignificant increase (+0.27 kg; P = 0.3). Prolactin levels decreased among those switched from risperidone (P < 0.0001) or conventionals (P = 0.05), but not for patients switched from olanzapine. EPS improved among those switched from conventionals (P < 0.0001) and to a lesser extent among those switched from risperidone (P < 0.01), but not in those changed from olanzapine (NS). Thus, in these studies, switching to ziprasidone in patients with continuing symptoms or side effects on their current medication was often associated with improved health status indices, lowered prolactin levels, or less EPS, with the magnitude benefit consistent with the known side-effect profile of the preswitch antipsychotic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.jcp.0000095347.32154.08

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Antipsychotic-induced weight gain: a comprehensive research synthesis

    Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · cited 2×

    “These findings regarding EPS, weight, lipid profile, elevated prolactin secretion, and general safety and tolerability are in accord with available data from other ziprasidone trials in patients with schizophrenia or schizoaffective disorder.(1,2,4,7) It is reported in separate paper that patients in all 3 switch stud…”
    BackgroundResultSelf-citation

Show all 1 references

Cited by

See all 123

Metadata

Authors
Weiden, P. J., Daniel, D. G., Simpson, G., & Romano, S. J.
Venue
Journal of Clinical Psychopharmacology
Published
2003-12
Volume
23
Issue
6
Pages
595-600
ISSN
0271-0749 (ISSN-L)
OpenAlex
W2002701207
Cited by
123
References
1
FWCI
7.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone. https://app.cochat.ai/papers/10.1097/01.jcp.0000095347.32154.08
The paper
Weiden, P. J., Daniel, D. G., Simpson, G., & Romano, S. J. (2003). Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/01.jcp.0000095347.32154.08

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.